## Saverio Alberti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4620547/publications.pdf

Version: 2024-02-01

94433 114465 4,941 132 37 63 citations h-index g-index papers 139 139 139 5621 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion. Oncogene, 2022, 41, 1795-1808.	5.9	15
2	A deterministic code for transcription factor-DNA recognition through computation of binding interfaces. NAR Genomics and Bioinformatics, 2022, 4, Iqac008.	3.2	0
3	Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. International Journal of Molecular Sciences, 2022, 23, 405.	4.1	11
4	The Hu2G10 mAb targets the cleaved-activated form of Trop-2 and exploits vulnerability of multiple human cancers Journal of Clinical Oncology, 2022, 40, e14548-e14548.	1.6	1
5	Abstract PD15-04: Trop-2 inactivation of E-cadherin drives triple negative breast cancer relapse. , 2021, , .		O
6	Tropâ€⊋ cleavage by ADAM10 is an activator switch for cancer growth and metastasis. Neoplasia, 2021, 23, 415-428.	5.3	35
7	Trop-2 inactivates E-cadherin and drives colon cancer metastasis Journal of Clinical Oncology, 2021, 39, e15576-e15576.	1.6	O
8	Abstract 2851: Trop-2 inactivates E-cadherin for metastatic diffusion in the absence of EMT., 2021, , .		0
9	Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer. Neoplasia, 2021, 23, 898-911.	5.3	24
10	Inactivation of E-cadherin by Trop-2 drives colon cancer metastasis Journal of Clinical Oncology, 2021, 39, 105-105.	1.6	2
11	PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes. BMC Cancer, 2019, 19, 747.	2.6	22
12	Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer. Cancer Communications, 2019, 39, 1-4.	9.2	4
13	Abandoning the Notion of Non-Small Cell Lung Cancer. Trends in Molecular Medicine, 2019, 25, 585-594.	6.7	207
14	Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast, 2019, 44, 33-38.	2.2	109
15	Pharmacogenetic and pharmacogenomic discovery strategies. Cancer Drug Resistance (Alhambra, Calif) Tj ETQq1	1.0.78431 2.1	.4 rgBT /Ove
16	Distinct lung cancer subtypes associate to distinct drivers of tumor progression. Oncotarget, 2018, 9, 35528-35540.	1.8	30
17	The 150 most important questions in cancer research and clinical oncology series: questions 15–24. Chinese Journal of Cancer, 2017, 36, 39.	4.9	9
18	The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget, 2017, 8, 58642-58653.	1.8	58

#	Article	IF	Citations
19	Novel domain-targeted anti-Trop-2 monoclonal antibodies to elicit therapeutic synergy against multiple human cancers Journal of Clinical Oncology, 2017, 35, e14002-e14002.	1.6	O
20	Abstract 4588: Novel anti-Trop-2 monoclonal antibodies with unique binding specificities show the rapeutic synergy against most human cancers. , 2017, , .		0
21	Abstract 367: Trop-2 activates a dormant Na+/K+-ATPase/PKC $\hat{l}$ ±/CD9/ezrin signaling axis to override the basal growth program of cancer cells. , 2017, , .		1
22	p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer, 2016, 16, 649.	2.6	25
23	Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors. Clinical Cancer Research, 2016, 22, 4197-4205.	7.0	38
24	Native, sequential protein folding via anchored N and C protein termini. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3189-E3191.	7.1	1
25	RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer. Journal of the National Cancer Institute, 2016, 108, djw143.	6.3	5
26	Comment on $\hat{a} \in \mathbb{C}$ Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice $\hat{a} \in \mathbb{C}$ Science Translational Medicine, 2016, 8, 350le2.	12.4	3
27	Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. Scientific Reports, 2016, 6, 19435.	3.3	102
28	Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics. EuPA Open Proteomics, 2016, 10, 31-41.	2.5	49
29	Lymph Node Micrometastases Do Influence Breast Cancer Outcome. Journal of Clinical Oncology, 2015, 33, 3977-3978.	1.6	4
30	Proteomics analysis of E-cadherin knockdown in epithelial breast cancer cells. Journal of Biotechnology, 2015, 202, 3-11.	3.8	38
31	A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer, 2015, 15, 417.	2.6	30
32	Epigenetic inheritance and the missing heritability. Human Genomics, 2015, 9, 17.	2.9	203
33	Trop-2 Is a Determinant of Breast Cancer Survival. PLoS ONE, 2014, 9, e96993.	2.5	131
34	Epigenetic heredity of human height. Physiological Reports, 2014, 2, e12047.	1.7	26
35	Trop-2 is a universal driver of tumor growth and metastatization – A new target for diagnostics and therapeutics. Journal of Biotechnology, 2014, 185, S9.	3.8	0
36	A Unique Four-Hub Protein Cluster Associates to Glioblastoma Progression. PLoS ONE, 2014, 9, e103030.	2.5	24

#	Article	IF	CITATIONS
37	The Trop-2 signalling network in cancer growth. Oncogene, 2013, 32, 1594-1600.	5.9	104
38	Human height genes and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 27-41.	7.4	22
39	Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. Molecular BioSystems, 2013, 9, 1127-1138.	2.9	29
40	Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene, 2013, 32, 222-233.	5.9	208
41	Overexpression of activated phospholipase Cl̂³1 is a risk factor for distant metastases in Tlâ€₹2, NO breast cancer patients undergoing adjuvant chemotherapy. International Journal of Cancer, 2013, 132, 1022-1031.	5.1	41
42	Cytoplasmic Trop-1/Ep-CAM Overexpression is Associated with a Favorable Outcome in Node-positive Breast Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 1128-1137.	1.3	9
43	Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Molecular BioSystems, 2012, 8, 1078.	2.9	91
44	Long-range Transcriptome Sequencing Reveals Cancer Cell Growth Regulatory Chimeric mRNA. Neoplasia, 2012, 14, 1087-49.	5.3	19
45	mTrop1/Epcam Knockout Mice Develop Congenital Tufting Enteropathy through Dysregulation of Intestinal E-cadherin/ $\hat{l}^2$ -catenin. PLoS ONE, 2012, 7, e49302.	2.5	67
46	EpCAM Expression Is an Indicator of Increased Incidence of Relapse in p53-Positive Breast Cancer. Cancer and Clinical Oncology, 2012, 2, .	0.2	0
47	Tropâ€2 inhibits prostate cancer cell adhesion to fibronectin through the β <sub>1</sub> integrinâ€RACK1 axis. Journal of Cellular Physiology, 2012, 227, 3670-3677.	4.1	58
48	p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features. Japanese Journal of Clinical Oncology, 2011, 41, 172-179.	1.3	59
49	Sentinel Node and Bone Marrow Micrometastases and Nanometastases. Current Breast Cancer Reports, 2010, 2, 96-106.	1.0	4
50	Letter to the Editor: Efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309–1. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 119-120.	7.4	5
51	An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. British Journal of Cancer, 2010, 103, 1835-1839.	6.4	30
52	A Dietary Tomato Supplement Prevents Prostate Cancer in TRAMP Mice. Cancer Prevention Research, 2010, 3, 1284-1291.	1.5	42
53	Abstract 5139: Trop2 modulates beta1 integrin-mediated adhesion and migration of prostate cancer cells. , 2010, , .		0
54	Abstract 5042: Trop-2 is a universal cancer growth stimulator through a ubiquitous signaling platform. , 2010, , .		0

#	Article	IF	CITATIONS
55	CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. American Journal of Translational Research (discontinued), 2010, 2, 135-44.	0.0	41
56	(-)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and post-translationally suppresses the cell proliferative protein TROP2 in human colorectal cancer cells. Anticancer Research, 2010, 30, 2497-503.	1.1	36
57	High expression of 90K (Macâ€⊋ BP) is associated with poor survival in nodeâ€negative breast cancer patients not receiving adjuvant systemic therapies. International Journal of Cancer, 2009, 124, 333-338.	5.1	36
58	Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers. Anticancer Research, 2009, 29, 951-63.	1.1	15
59	Energyâ€based prediction of amino acidâ€nucleotide base recognition. Journal of Computational Chemistry, 2008, 29, 1955-1969.	3.3	44
60	Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer. European Journal of Cancer, 2008, 44, 2696-2704.	2.8	18
61	A Bicistronic <i>CYCLIN D1-TROP2</i> mRNA Chimera Demonstrates a Novel Oncogenic Mechanism in Human Cancer. Cancer Research, 2008, 68, 8113-8121.	0.9	76
62	Protocol for high-sensitivity/long linear-range spectrofluorimetric DNA quantification using ethidium bromide. BioTechniques, 2007, 43, 173-176.	1.8	39
63	Trop-1 are conserved growth stimulatory molecules that mark early stages of tumor progression. Cancer, 2007, 110, 452-464.	4.1	24
64	The forgotten variables of DNA array hybridization. Trends in Biotechnology, 2006, 24, 443-448.	9.3	26
65	Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. Journal of Cellular Physiology, 2006, 207, 23-29.	4.1	75
66	Changes of Topoisomerase Ilα Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival. Clinical Cancer Research, 2006, 12, 1501-1506.	7.0	24
67	Molecular Subtyping of Breast Cancer from Traditional Tumor Marker Profiles Using Parallel Clustering Methods. Clinical Cancer Research, 2006, 12, 781-790.	7.0	41
68	Axillary Lymph Node Nanometastases Are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 6696-6701.	7.0	71
69	Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1705, 103-120.	7.4	27
70	Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene. Oncogene, 2003, 22, 1668-1677.	5.9	34
71	Detection and analysis of spliced chimeric mRNAs in sequence databanks. Nucleic Acids Research, 2003, 31, 17e-17.	14.5	44
72	Prognostic value of mutations in TP53 and RAS genes in breast cancer. International Journal of Biological Markers, 2003, 18, 49-53.	1.8	4

#	Article	IF	Citations
73	Signaling protein networks as targets of new antineoplastic drugs. International Journal of Biological Markers, 2003, 18, 57-61.	1.8	1
74	Oligomerization of DsRed is required for the generation of a functional red fluorescent chromophore. FEBS Letters, 2002, 525, 13-19.	2.8	49
75	Corrigendum to "Green fluorescent flowers― Plant Science, 2002, 162, 645.	3.6	0
76	Presentation of native TROPâ€2 tumor antigens to human cytotoxic T lymphocytes by engineered antigenâ€presenting cells. International Journal of Cancer, 2002, 101, 353-359.	5.1	25
77	Green fluorescent flowers. Plant Science, 2001, 161, 961-968.	3.6	27
78	Efficient GFP mutations profoundly affect mRNA transcription and translation rates. FEBS Letters, 2001, 492, 151-155.	2.8	36
79	Molecular Prognostic Indicators for Breast Cancer. Tumori, 2001, 87, 23-25.	1.1	4
80	Trop Molecules as Targets for Anti-Tumor Immunotherapy in Man. Tumori, 2001, 87, 5-8.	1.1	2
81	Nuclear changes in necrotic HL-60 cells. Journal of Cellular Biochemistry, 2001, 81, 19-31.	2.6	28
82	Green Fluorescent Protein variants fold differentially in prokaryotic and eukaryotic cells. Journal of Cellular Biochemistry, 2001, 81, 117-128.	2.6	33
83	Cyclin D1 gene contains a cryptic promoter that is functional in human cancer cells. Genes Chromosomes and Cancer, 2001, 31, 209-220.	2.8	20
84	Assignment <footref rid="foot01"><sup>1</sup></footref> of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenetic and Genome Research, 2001, 92, 164-165.	1.1	62
85	Epidermal Growth Factor-Like Repeats Mediate Lateral and Reciprocal Interactions of Ep-CAM Molecules in Homophilic Adhesions. Molecular and Cellular Biology, 2001, 21, 2570-2580.	2.3	159
86	Correlative Light-Electron Microscopy Reveals the Tubular-Saccular Ultrastructure of Carriers Operating between Golgi Apparatus and Plasma Membrane. Journal of Cell Biology, 2000, 148, 45-58.	5.2	304
87	Large and diverse numbers of human diseases with HIKE mutations. Human Molecular Genetics, 2000, 9, 1001-1007.	2.9	23
88	The molecular determinants of the efficiency of green fluorescent protein mutants. Histology and Histopathology, 2000, 15, 101-7.	0.7	14
89	Molecular Cloning and Functional Characterization of Brefeldin A-ADP-ribosylated Substrate. Journal of Biological Chemistry, 1999, 274, 17705-17710.	3.4	92
90	Protein tags enhance GFP folding in eukaryotic cells. Nature Biotechnology, 1999, 17, 1046-1046.	17.5	21

#	Article	IF	Citations
91	Evolution of the genetic code, protein synthesis and nucleic acid replication. Cellular and Molecular Life Sciences, 1999, 56, 85-93.	5 <b>.</b> 4	10
92	Red GFP and endogenous porphyrins. Current Biology, 1999, 9, R391-R393.	3.9	9
93	HIKE, a candidate protein binding site for PH domains, is a major regulatory region of G? proteins. , 1999, 35, 360-363.		12
94	Cloning of the murine TROP2 gene: Conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2., 1998, 75, 324-330.		69
95	Human TROP-2 is a tumor-associated calcium signal transducer. International Journal of Cancer, 1998, 76, 671-676.	5.1	180
96	A phosphoinositide-binding sequence is shared by PH domain target moleculesâ€"a model for the binding of PH domains to proteins. , 1998, 31, 1-9.		24
97	Cloning of the murine TROP2 gene: Conservation of a PIP2â€binding sequence in the cytoplasmic domain of TROPâ€2. International Journal of Cancer, 1998, 75, 324-330.	5.1	1
98	Detection of the Receptor for the Human Urokinase-type Plasminogen Activator Using Fluoresceinated uPA. Journal of Histochemistry and Cytochemistry, 1997, 45, 1307-1313.	2.5	4
99	The origin of the genetic code and protein synthesis. Journal of Molecular Evolution, 1997, 45, 352-358.	1.8	26
100	Development of ulcerative colitis: evidence from animal models. Trends in Molecular Medicine, 1996, 2, 272-274.	2.6	1
101	A high affinity T cell receptor?. Immunology and Cell Biology, 1996, 74, 292-297.	2.3	6
102	High-efficiency expression gene cloning by flow cytometry Journal of Histochemistry and Cytochemistry, 1996, 44, 629-640.	2.5	25
103	Expression of HLA Class I Genes in Meiotic and Post-Meiotic Human Spermatogenic Cells1. Biology of Reproduction, 1996, 55, 99-110.	2.7	44
104	Cloning of the gene encoding TROP-2, a cell-surface glycoprotein expressed by human carcinomas. International Journal of Cancer, 1995, 62, 610-618.	5.1	126
105	In vivo targeting of integrin receptors in human skin xenografts by intravenously applied antibodies. Archives of Dermatological Research, 1994, 286, 6-11.	1.9	8
106	MRC OX19 recognizes the rat CD5 surface glycoprotein, but does not provide evidence for a population of CD5bright B cells. European Journal of Immunology, 1994, 24, 585-592.	2.9	33
107	DNA methylation prevents the amplification of TROP1, a tumor-associated cell surface antigen gene Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5833-5837.	7.1	41
108	Biochemical and immunological characterization of the human carcinoma-associated antigen MH 99/KS 1/4. International Journal of Cancer, 1993, 55, 988-995.	5.1	42

#	Article	IF	CITATIONS
109	Tâ€cellâ€receptor engagement and tumor ICAMâ€1 upâ€regulation are required to byâ€pass low susceptibility of melanoma cells to autologous CTLâ€mediated lysis. International Journal of Cancer, 1993, 53, 994-1001.	5.1	33
110	Biochemical Characterization of Trop-2, a Cell Surface Molecule Expressed by Human Carcinomas: Formal Proof that the Monoclonal Antibodies T16 and MOv-16 Recognize Trop-2. Hybridoma, 1992, 11, 539-545.	0.6	67
111	Molecular Cloning of the Rat CD5 Gene. Annals of the New York Academy of Sciences, 1992, 651, 82-83.	3.8	2
112	Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: Role of ICAM-1 defined by antibody blocking and gene transfer. European Journal of Immunology, 1992, 22, 2255-2260.	2.9	30
113	Membrane association and shedding of the GPI-anchored Ca-MOv18 antigen in human ovary carcinoma cells. International Journal of Cancer, 1992, 51, 499-505.	5.1	18
114	Molecular cloning, reconstruction and expression of the gene encoding the alpha-chain of the bovine CD8-definition of three peptide regions conserved across species. Immunology, 1992, 76, 95-102.	4.4	5
115	Immunofluorescence analysis in flow cytometry: better selection of antibody-labeled cells after fluorescence overcompensation in the red channel Journal of Histochemistry and Cytochemistry, 1991, 39, 701-706.	2.5	20
116	Expression of 38-kD Cell-Surface Glycoprotein in Transformed Keratinocyte Cell Lines, Basal Cell Carcinomas, and Epithelial Germs. Journal of Investigative Dermatology, 1990, 95, 74-82.	0.7	37
117	Higher transfection efficiency of genomic DNA purified with a guanidinium thiocyanate-based procedure. Nucleic Acids Research, 1990, 18, 351-353.	14.5	27
118	The Ca-MOv18 molecule, a cell-surface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositol. Biochemical and Biophysical Research Communications, 1990, 171, 1051-1055.	2.1	31
119	Transfection into mouse L cells of genes encoding two serologically and functionally distinct bovine class I MHC molecules from a MHC-homozygous animal: evidence for a second class I locus in cattle. Immunology, 1990, 70, 20-6.	4.4	54
120	DNA methylation prevents transfection of genes for specific surface antigens Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 8391-8394.	7.1	40
121	A single laser method for subtraction of cell autofluorescence in flow cytometry. Cytometry, 1987, 8, 114-119.	1.8	95
122	Metastatic Growth of a Murine Tumor: Evidence of Dissemination to the Lungs in the Absence of Subcutaneous Growth. Tumori, 1986, 72, 345-350.	1.1	1
123	DNA Transfection : Gene Regulation, Gene Amplification and Gene Cloning. Juntendol, Igaku, 1986, 32, 423-425.	0.1	O
124	Relationship between large granular lymphocytes and NK-1.2+ cells from normal and poly(inosinic:cytidylic acid) (poly(I:C))-treated mice. Clinical Immunology and Immunopathology, 1985, 36, 81-94.	2.0	0
125	Large granular lymphocytes from murine blood and intestinal epithelium: Comparison of surface antigens, natural killer activity, and morphology. Clinical Immunology and Immunopathology, 1985, 36, 227-238.	2.0	10
126	Effect of hydrocortisone on the macrophage content, growth and metastasis of transplanted murine tumors. International Journal of Cancer, 1984, 33, 95-105.	5.1	36

## SAVERIO ALBERTI

#	Article	IF	CITATION
127	Preservation of cells sorted individually onto microscope slides with a fluorescence-activated cell sorter. Cytometry, 1984, 5, 644-647.	1.8	8
128	In Vivo Treatments with Cyclosporin-A: Different Effects on Cell-Mediated Immunity in Mice. , 1984, , 293-302.		0
129	Transfection and cloning of genes for membrane antigens using the FACS. Medical Oncology and Tumor Pharmacotherapy, 1984, 1, 219-224.	1.1	1
130	Lack of Association between BK Virus and Ependymomas, Malignant Tumors of Pancreatic Islets, Osteosarcomas and Other Human Tumors. Intervirology, 1981, 15, 10-18.	2.8	24
131	Effects of in vivo treatments with cyclosporin-A on mouse cell-mediated immune responses. International Journal of Immunopharmacology, 1981, 3, 357-364.	1.1	36
132	Morphological characterization of a cell population responsible for natural killer activity. Immunology, 1981, 43, 663-8.	4.4	114